Evidence map›Paper›PMID 26270486›Full record

ArticlePloS one2015

In Silico Adoption of an Orphan Nuclear Receptor NR4A1.

Harald Lanig, Felix Reisen, David Whitley, Gisbert Schneider, Lee Banting, Timothy Clark

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Harald LanigComputer-Chemie-Centrum der Friedrich-Alexander-Universität Erlangen-Nürnberg, Nägelsbachstraße 25, 91052, Erlangen, Germany.
Felix ReisenETH Zürich, Institute of Pharmaceutical Sciences, Wolfgang-Pauli-Straße 10, 8093, Zürich, Switzerland.
David WhitleyCentre for Molecular Design, School of Pharmacy and Biomolecular Sciences, University of Portsmouth, King Henry Building, Portsmouth, PO1 2DY, United Kingdom.
Gisbert SchneiderETH Zürich, Institute of Pharmaceutical Sciences, Wolfgang-Pauli-Straße 10, 8093, Zürich, Switzerland.
Lee BantingSchool of Pharmacy and Biomolecular Sciences, University of Portsmouth, St. Michael's Building, White Swan Road, Portsmouth, PO1 2DT, United Kingdom.
Timothy ClarkComputer-Chemie-Centrum der Friedrich-Alexander-Universität Erlangen-Nürnberg, Nägelsbachstraße 25, 91052, Erlangen, Germany; Centre for Molecular Design, School of Pharmacy and Biomolecular Sciences, University of Portsmouth, King Henry Building, Portsmouth, PO1 2DY, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 4.1 μs molecular dynamics simulation of the NR4A1 (hNur77) apo-protein has been undertaken and a previously undetected druggable pocket has become apparent that is located remotely from the 'traditional' nuclear receptor ligand-binding site. A NR4A1/bis-indole ligand complex at this novel site has been found to be stable over 1 μs of simulation and to result in an interesting conformational transmission to a remote loop that has the capacity to communicate with a NBRE within a RXR-α/NR4A1 heterodimer. Several features of the simulations undertaken indicate how NR4A1 can be affected by alternate-site modulators.

Indexed as

Binding SitesComputer SimulationHumansLigandsModels, MolecularMolecular Dynamics SimulationNuclear Receptor Subfamily 4, Group A, Member 1Protein BindingProtein Structure, SecondaryRetinoid X Receptor alphaLigandsNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Retinoid X Receptor alpha

Identifiers

PMID26270486
PMCPMC4535767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.